
Opinion|Videos|February 16, 2026
Opportunities for Health Systems to Integrate APPs Into Alzheimer Disease Care
Author(s)Ken Cohen, MD, FACP
Panelists discuss how system-wide APP integration improves coordinated, efficient Alzheimer care.
Advertisement
Episodes in this series

Panelists discuss how incorporating advanced practice providers (APPs) into structured health-system pathways expands capacity for Alzheimer diagnosis and management. Their integration supports timely evaluations and consistent follow-up.
Panelists discuss how organizational policies that empower APPs enhance operational efficiency, improve patient throughput, and alleviate physician workload. Systemwide collaboration ensures equitable care access.
Panelists discuss how embedding APPs within multidisciplinary teams also reduces long-term costs and supports sustainable models for chronic neurodegenerative disease management.
Advertisement
Related to this article

Among 821,327 outpatients, cystatin C–based eGFR at least 30% below creatinine-based eGFR was linked to higher death and heart failure rates.

Faculty say heart failure patients miss iron deficiency care when no one owns it; pharmacist-led workflows may help close the gap.

The FDA approved cemdisiran (Livsayis; Regeneron), a subcutaneous siRNA dosed every 3 months, for AChR-positive generalized myasthenia gravis.

In a single-clinic study, 61.5% of patients with psoriasis screened positive for psoriatic arthritis using a validated questionnaire.

Pharmacy teams can shorten the time of Medicare GLP-1 Bridge approvals, but 2027 approval windows may leave patients without titration check-ins.

An employer coalition's new guide outlines how workplaces can prevent and manage diabetes, from benefit design to accommodations.

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.
Advertisement
Advertisement
Trending on AJMC
1
Complicated UTI Care Strained by Unclear Goals, Access Gaps
2
FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis
3
Hepatitis B Screening Gaps Persist as Functional Cure Option Arrives
4
FDA Approves Oral Giredestrant Regimen for ESR1-Mutated Breast Cancer
5

